FDA Approval in Myeloma, Expanded Approval in Melanoma, GI Cancer Symposium Highlights, and More

The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

Data for fixed-duration regimens in CLL suggest benefits over chemoimmunotherapy but still require improvements for high-risk patients.

A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.